Figure 5. GABARAP suppresses breast cancer progression in vivo. (A) A total of 5×106 GABARAP-knockdown or control cells were injected subcutaneously into the left side of each of nude mouse. Vector group, mice inoculated with control UACC-812 cells; shRNA group, mice inoculated with GABARAP silenced UACC-812 cells; vector control+LY294002 group, mice inoculated with control UACC-812 cells and treated with LY294002; shRNA+LY294002 group, mice inoculated with GABARAP silenced UACC-812 cells and treated with LY294002. Representative images of nude mice and tumors at day 28 after inoculation of UACC-812 cells with or without shRNA-mediated silencing of GABARAP. (B) Tumor growth curves in 4 groups of nude mice. The data are presented as the means ± SDs. P values were calculated using Student’s t-test. (C) The tumor weights were measured. The data were statistically analyzed using Student’s t-test, and the mean ± SEM is shown. (D) Immunostaining of proteins in tumors from the vector control group and GABARAP-shRNA group. First column, H&E staining; second column, immunostaining for GABARAP; third column, immunostaining for E-cadherin; fourth column, immunostaining for MMP2; and fifth column, immunostaining for p-mTOR. Magnification, 400×. (*P < 0.05; **P < 0.01; ***P < 0.001).